Federal regulators have approved a groundbreaking therapy developed by Denali Therapeutics for Hunter syndrome, a rare genetic condition. This marks the company's first FDA approval in the United States, sending their stock price higher.
Federal health regulators announced Wednesday they have given the green light to a new treatment for a rare inherited disease developed by Denali Therapeutics.
This regulatory approval represents a milestone achievement for the pharmaceutical company, marking their inaugural FDA clearance in the United States.
Following the announcement, Denali’s stock price climbed 4.2% to reach $21.86 per share.
The newly approved medication, which will be sold under the brand name Avlayah, serves as an enzyme replacement treatment designed to combat Hunter syndrome. This uncommon inherited condition causes harmful accumulation of specific sugar compounds throughout the brain and other organs.
Hunter syndrome develops when patients lack sufficient amounts of the enzyme iduronate-2-sulfatase, leaving their bodies unable to properly process large sugar molecules known as glycosaminoglycans.
Los Angeles Jury Delivers Verdict in Major Social Media Addiction Lawsuit
London Museum Showcases Century of Schiaparelli’s Artistic Fashion Legacy
500 Migrants March in Southern Mexico Demanding Work Authorization Papers
United Nations Approves Resolution Calling Slavery ‘Gravest Crime Against Humanity’